Terminally differentiated B cell, the plasma cell, is the sole cell type capable of producing
antibodies in our body. Over the past 30 years, the identification of many key molecules …

Multiple myeloma (MM) is a challenging hematological cancer which typically grows in bone
marrow. MM accounts for 10% of hematological malignancies and 1.8% of cancers. The …

Clinical progress in multiple myeloma (MM), an incurable plasma cell (PC) neoplasia, has
been driven by therapies that have limited applications beyond MM/PC neoplasias and do …

Abstract tRNA are post-transcriptionally modified by chemical modifications that affect all
aspects of tRNA biology. An increasing number of mutations underlying human genetic …

It has been previously shown that (never in mitosis gene A)‐related kinase 2 (NEK2) is
upregulated in multiple myeloma (MM) and contributes to drug resistance. However, the …

Immunomodulatory drugs (IMiDs) including lenalidomide and pomalidomide bind cereblon
(CRBN) and activate the CRL4CRBN ubiquitin ligase to trigger proteasomal degradation of …

Immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide show remarkable
antitumor activity in multiple myeloma (MM) via directly inhibiting MM-cell growth in the bone …

The transcriptional coactivator cAMP response element binding protein (CREB)-binding
protein (CBP) and its homologue p300 have emerged as attractive therapeutic targets for …

Lenalidomide is a derivative of thalidomide and belongs to the class of drugs known as the
immunomodulatory drugs (IMiDs). The IMiDs have played a large role in improving the …

Immunomodulatory drugs (IMiDs) have markedly improved patient outcome in multiple
myeloma (MM); however, resistance to IMiDs commonly underlies relapse of disease. Here …